Company Overview of Chemokine Therapeutics Corp.
Chemokine Therapeutics Corp., a development-stage company, focuses on the development of peptide-based drugs for human diseases. The company focuses on the area of chemokines, small proteins that regulate various physiological functions primarily in relation to the immune system. Its drug candidates in human clinical trials include CTCE-9908, which is in phase II clinical trials for the treatment of metastasis and angiogenesis cancers; and CTCE-0214 that is in phase I clinical trials stage for hematological support, and for neutrophil, platelet, and stem cell mobilization. The company’s other products comprise CTCE-0422, which is in preclinical development stage for wound healing; and CTCE-0...
1727 West Broadway
Vancouver, BC V6J 4S5
Founded in 1998
Key Executives for Chemokine Therapeutics Corp.
Chief Executive Officer and President
Assistant Secretary and General Counsel
Director of Investor Relations
Vice President of Corporate Communications
Compensation as of Fiscal Year 2012.
Chemokine Therapeutics Corp. Key Developments
SEC Revokes Registration Of Registered Securities Of Chemokine Therapeutics
Apr 24 12
An administrative law judge issued an order making findings and revoking registrations by default as to Chemokine Therapeutics Corp. The default order finds that the allegations in the order instituting proceedings are true. The company as issuer of securities registered pursuant to Section 12(g) of the Securities Exchange Act of 1934 (Exchange Act), failed to comply with Exchange Act Section 13(a) and Exchange Act Rules 13a-1 and 13a-13 by failing to file required periodic reports with the Securities and Exchange Commission (SEC). As a result, the administrative law judge ordered the revocation of the registration of each class of company’s registered securities.
SEC Orders Hearings On Registration Suspension Or Revocation Against Chemokine Therapeutics For Failure To Make Required Periodic Filings
Feb 17 12
In conjunction with this trading suspension, Securities and Exchange Commission (SEC or the Commission) instituted public administrative proceedings to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Chemokine Therapeutics Corp. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company is delinquent in their required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceedings.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries